Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Closes Solexa Acquisition

NEW YORK (GenomeWeb News) —Illumina today said it has closed its $600 million acquisition of Solexa.
 
"We are excited to join the two companies, creating the only company with genome-scale technology for genotyping, gene expression, and sequencing, the three cornerstones of modern genetic analysis," Illumina CEO Jay Flatley said in a statement.
 
"With Solexa's recent technical achievements we look forward to the rapid commercialization of our next-generation sequencing platform," he added.
 
In connection with the merger, Illumina has increased the size of its board from eight to 10 members, adding Blaine Bowman and Roy Whitfield, both of whom were Solexa directors.
 
Illumina will report its fourth quarter financial results on Feb. 1.
The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.